Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Reports Increased Q1 Revenues; Plans to Shut Germantown Testing Facility by Fall

NEW YORK, April 28 (GenomeWeb News) - Orchid BioSciences yesterday reported a 9-percent increase in revenues and smaller losses for the first quarter. The company also said it will close its Germantown, Md., DNA testing lab and consolidate all of its USforensic testing services to its Dallas, Texas, and Nashville, Tenn.sites.


Revenues for the quarter increased to $14.5 million from $13.3 million during the same quarter in 2004.


Research and development costs came down slightly, to $397,000 from $417,000 during the year-ago period.


Orchid's net loss fell to $1.7 million, or $.07 per share, from $6.9 million, or $.41 per share, during the first quarter in 2004.


As of March 31, Orchid had $24.1 million in cash and cash equivalents, and $6 million in short-term investments.


Orchid said it will close its Germantownfacility by Sept. 30 in order to lower its costs by $2 million to $2.5 million per year and to make its DNA testing services more efficient and scalable. The company said it plans to keep key staff members from the Germantownsite.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.